Clinical Trials Logo

Hemolytic Disease of Newborn clinical trials

View clinical trials related to Hemolytic Disease of Newborn.

Filter by:
  • None
  • Page 1

NCT ID: NCT04218318 Recruiting - Clinical trials for Neonatal Hyperbilirubinemia

Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn. Objectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in term and late preterm neonates with hemolytic disease of newborn.

NCT ID: NCT00917007 Withdrawn - Neonatal Jaundice Clinical Trials

Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis

Start date: June 2009
Phase:
Study type: Observational

The purpose of this research study is to more accurately measure the amount of true red blood cell breakdown (hemolysis) in newborn babies with potentially problematic blood type mismatch with their mothers (ABO incompatibility), and to examine how the true level of red blood cell destruction relates to other laboratory tests obtained in newborns with jaundice. A better understanding of the true amount of red blood cell destruction that is caused by blood type mismatch, as well as how it relates with other laboratory tests ordered for ABO incompatibility and red blood cell destruction, would help avoid unnecessary testing, treatment and prolonged hospital stays in such babies.

NCT ID: NCT00004381 Completed - Hyperbilirubinemia Clinical Trials

Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia

Start date: December 1999
Phase: Phase 2
Study type: Interventional

OBJECTIVES: I. Compare the efficacy of preventive vs. therapeutic tin mesoporphyrin in direct Coombs' test-positive ABO hemolytic disease of the newborn and glucose-6-phosphate dehydrogenase deficiency in infants living in Greece. II. Assess the safety of tin mesoporphyrin in high-risk newborns.